These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 27348300)

  • 1. Occurrence of JAK2V617F mutation in previously triple negative essential thrombocythemia.
    Benetatos L
    Leuk Lymphoma; 2017 Feb; 58(2):503-504. PubMed ID: 27348300
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia.
    Kittur J; Knudson RA; Lasho TL; Finke CM; Gangat N; Wolanskyj AP; Li CY; Wu W; Ketterling RP; Pardanani A; Tefferi A
    Cancer; 2007 Jun; 109(11):2279-84. PubMed ID: 17440984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis.
    Yönal İ; Dağlar-Aday A; Akadam-Teker B; Yılmaz C; Nalçacı M; Yavuz AS; Sargın FD
    Turk J Haematol; 2016 Jun; 33(2):94-101. PubMed ID: 25913509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A case of JAK2V617F-positive essential thrombocythemia where allele burden was reduced by a PD-1 inhibitor.
    Hara R; Kawada H; Kikuti YY; Kikkawa E; Harada K; Aoyama Y; Ogiya D; Toyosaki M; Suzuki R; Machida S; Ohmachi K; Onizuka M; Ogawa Y; Masuda R; Iwazaki M; Nakamura N; Ando K
    Int J Hematol; 2021 Apr; 113(4):606-610. PubMed ID: 33389657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Essential differences in clinical and bone marrow features in BCR/ABL-positive thrombocythemia compared to thrombocythemia in the BCR/ABL-negative myeloproliferative neoplasms essential thrombocythemia and polycythemia vera.
    Michiels JJ; Pich A; De Raeve H; Gadisseur A
    Acta Haematol; 2015; 133(1):52-5. PubMed ID: 25116159
    [No Abstract]   [Full Text] [Related]  

  • 6. JAK2V617F mutation and allele burden are associated with distinct clinical and morphological subtypes in patients with essential thrombocythaemia.
    Pich A; Riera L; Beggiato E; Nicolino B; Godio L; Campisi P; Sismondi F; di Celle PF
    J Clin Pathol; 2012 Oct; 65(10):953-5. PubMed ID: 22718845
    [No Abstract]   [Full Text] [Related]  

  • 7. Essential Thrombocythemia Associated With Germline JAK2 G571S Variant and Somatic CALR Type 1 Mutation.
    Panovska-Stavridis I; Eftimov A; Ivanovski M; Pivkova-Veljanovska A; Cevreska L; Hermouet S; Dimovski AJ
    Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):e55-7. PubMed ID: 27009537
    [No Abstract]   [Full Text] [Related]  

  • 8. JAK2V617F mutation is associated with special alleles in essential thrombocythemia.
    Hsiao HH; Liu YC; Tsai HJ; Lee CP; Hsu JF; Lin SF
    Leuk Lymphoma; 2011 Mar; 52(3):478-82. PubMed ID: 21281225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Correlations of jak2v617f mutation with clinical and laboratory findings in primary thrombocythemia patients].
    Xia J; Xu W; Zhang SJ; Sun XM; Duan LM; Li WD; Qiou HX; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Apr; 16(2):416-20. PubMed ID: 18426677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
    Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O
    Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dysplasia of all granulocyte lineages in myelodysplastic evolution of essential thrombocythemia.
    Bain BJ; Garnett C; Deplano S; Naresh K; Kanfer E
    Am J Hematol; 2013 May; 88(5):426. PubMed ID: 23460316
    [No Abstract]   [Full Text] [Related]  

  • 13. Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia.
    Shirane S; Araki M; Morishita S; Edahiro Y; Sunami Y; Hironaka Y; Noguchi M; Koike M; Sato E; Ohsaka A; Komatsu N
    Int J Hematol; 2015 Feb; 101(2):148-53. PubMed ID: 25522845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative assessment of the JAK2 V617F allele burden: equivalent levels in peripheral blood and bone marrow.
    Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
    Leukemia; 2008 Jan; 22(1):194-5. PubMed ID: 17625603
    [No Abstract]   [Full Text] [Related]  

  • 15. The impact of JAK2V617F mutation on different types of thrombosis risk in patients with essential thrombocythemia: a meta-analysis.
    Qin Y; Wang X; Zhao C; Wang C; Yang Y
    Int J Hematol; 2015 Aug; 102(2):170-80. PubMed ID: 25997869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The significance of bone marrow biopsy and JAK2V617F mutation in the differential diagnosis between the "early" prepolycythemic phase of polycythemia vera and essential thrombocythemia.
    Gianelli U; Iurlo A; Vener C; Moro A; Fermo E; Bianchi P; Graziani D; Radaelli F; Coggi G; Bosari S; Deliliers GL; Zanella A
    Am J Clin Pathol; 2008 Sep; 130(3):336-42. PubMed ID: 18701405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlative study between the JAK2V617F mutation and thrombosis in patients with myeloproliferative neoplasm.
    Li ZC; Fu HJ; Wang ZM; Yang S; Xu HZ
    Genet Mol Res; 2016 Aug; 15(3):. PubMed ID: 27706633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel Janus Kinase 2 mutation involving 14th intron splicing region in a patient with essential thrombocythemia.
    Sun X; Xu Z; Xie L; Lai R; Zhu X; Zhang W; Xie W
    Leuk Lymphoma; 2009 Dec; 50(12):2089-91. PubMed ID: 20001246
    [No Abstract]   [Full Text] [Related]  

  • 19. Identification of JAK2V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera.
    Ganly P; Hanrahan V; Baker B; Romeril K
    Am J Hematol; 2007 Jan; 82(1):80-2. PubMed ID: 16924638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absence of FTL3 mutations in patients with JAK2V617F mutation negative essential thrombocythemia.
    Medeiros BC; Zhang T; Lipton JH; Kamel-Reid S
    Am J Hematol; 2007 Apr; 82(4):293-4. PubMed ID: 17013813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.